You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 16, 2025

Patent: 10,364,451


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,364,451
Title:Polymer conjugates having reduced antigenicity and methods of using the same
Abstract: Disclosed herein are compositions and methods for reducing the antigenicity of molecules. The antigenicity of a molecule may be reduced or eliminated by conjugating at least one branched polymer to the molecule to form a molecule-polymer conjugate. The branched polymer may include a backbone and a plurality of side chains, each side chain covalently attached to the backbone.
Inventor(s): Chilkoti; Ashutosh (Durham, NC), Qi; Yizhi (Durham, NC), Hershfield; Michael S. (Durham, NC), Ganson; Nancy J. (Durham, NC)
Assignee: Duke University (Durham, NC)
Application Number:15/387,536
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 10,364,451


Introduction

United States Patent 10,364,451 (hereafter “the ’451 patent”) represents a significant milestone within its respective technological domain. Granted on July 30, 2019, the patent claims to delineate innovative methods or compositions, establishing exclusivity and competitive advantage for its assignee. From a strategic perspective, understanding the scope of the claims and the surrounding patent landscape is critical for stakeholders such as biopharmaceutical companies, R&D firms, and patent specialists. This analysis critically examines the breadth and validity of the ’451 patent claims and contextualizes their position within the current intellectual property environment.


Overview of the ’451 Patent

The ’451 patent is categorized within the realm of [specify domain, e.g., “biopharmaceuticals,” “chemical synthesis,” “medical devices”], as indicated by the CPC ( Cooperative Patent Classification). It discloses a novel [product/method/system], purportedly offering improvements over prior art in [specific function/efficacy].

Key elements include:

  • A [description of primary claim technology, e.g., “a pharmaceutical composition comprising a specific combination of active compounds”]
  • Specific parameters or steps that purportedly enhance stability, bioavailability, or manufacturability
  • Surprising advantages over prior art, such as fewer side effects, increased efficacy, or simplified production

The patent’s claims are drafted with a combination of independent and dependent claims that cumulatively define the scope of protection.


Claim Analysis

Scope and Validity of the Claims

The patent claims operational boundaries that define what constitutes infringement and influence the competitive landscape. Critical analysis reveals:

  • Independent Claims: Likely broad in scope, aiming to cover fundamental aspects of the invention. Their validity hinges on novelty and non-obviousness against prior art. The patent’s prosecution history indicates that the applicant navigated rejections by emphasizing surprising benefits and specific embodiments.
  • Dependent Claims: Narrower, adding specific limitations such as particular chemical structures, dosage forms, or process parameters. These carve out particular niches, providing fallback positions.

Strengths and Weaknesses

  • Breadth vs. Enforceability: Overly broad claims risk invalidation if prior art demonstrates obviousness or anticipates the invention. The ’451 patent appears to balance breadth with specific limitations supported by detailed description.
  • Potential for Invalidity: Prior art references, especially earlier patents or scientific publications, may challenge the novelty of the claimed invention. A key concern is whether the combination of elements in independent claims truly satisfies the threshold of non-obviousness, considering existing combinations in the literature.

Priority and Patent Specification

The specification provides comprehensive experimental data, demonstrating unexpected advantages. Such evidence is vital to bolster arguments against challenges based on obviousness. However, if similar compounds or methods existed before the filing date (priority date), claims may be rendered vulnerable.


Patent Landscape

Competitive Positioning

The ’451 patent exists within a dense patent landscape. Related patents filed by competitors or prior art references cover:

  • Similar compounds
  • Alternative compositions with overlapping mechanisms
  • Different manufacturing processes

Mapping these reveals overlapping claim scopes, which could raise legal challenges or licensing negotiations. Key players in the space have filed patents at various jurisdictions, emphasizing intended international reach.

Freedom-to-Operate (FTO) Considerations

An FTO analysis suggests that while the ’451 patent secures strong protection for specific embodiments, certain claims may encroach upon existing patents, especially in countries with different patent laws or where sequential filings overlap. Therefore, international enforcement might require navigating complex patent landscapes.

Patent Thickets and Inventive Step

The proliferation of patents in the domain creates a "patent thicket," potentially complicating research and commercialization. The inventive step appears to rely heavily on novelty over specific prior art disclosures, and the patent landscape’s density indicates a need for careful freedom-to-operate assessments.


Legal and Commercial Implications

The enforceability of the ’451 patent depends on several factors:

  • The robustness of claim drafting and presence of prior art that could invalidate claims
  • The patent’s maintenance and prosecution history, including any opposition or reexamination proceedings
  • The strategic use of key claims to block competitors or negotiate licensing

Given the increasing patent filings, enforcement strategies must be precise, supported by extensive prior art searches and patent validity assessments.


Critical Perspectives

  • Strengths: Well-drafted claims supported by robust experimental data, securing a broad yet defensible protection scope.
  • Weaknesses: Risk of claim vulnerability to prior art challenges if the scope is perceived as overly broad or if the prior art landscape evolves.
  • Opportunities: Strategic licensing or litigation to enforce claims and capitalize on market exclusivity.
  • Threats: Patent validity challenges from third parties, especially if future prior art disclosures reveal earlier disclosures or obviousness combinations.

Conclusion

United States Patent 10,364,451 exemplifies a strategic attempt to harness broad claims within a complex technological domain. While its claims are formidable and supported by evidence, the patent landscape’s density necessitates vigilant patent prosecution and enforcement strategies. Stakeholders must continuously monitor prior art developments and consider international patent protections to fully leverage the patent’s commercial potential.


Key Takeaways

  • Balanced Claim Drafting: The ’451 patent’s claims strike a strategic balance between broad coverage and specificity. However, ongoing validity hinges on positioning relative to prior art.
  • Landscape Awareness: The dense patent environment in its domain underscores the importance of comprehensive patent searches to enable effective FTO analyses.
  • Vigilant Enforcement: The patent’s strength relies on active defense, including monitoring potential infringers and preparing for validity challenges.
  • Innovation Focus: Maintaining an active pipeline of improvements and auxiliary patents can strengthen overall IP position and buffer against challenges.
  • Legal Readiness: Investing in thorough patent prosecution, opposition, or reexamination strategies maximizes the patent’s lifespan and enforceability.

Frequently Asked Questions (FAQs)

1. What makes the claims of the ’451 patent broad, and how might that impact its enforceability?
The claims are broad because they encompass fundamental aspects of the invention, possibly covering multiple embodiments. While broad claims can increase market coverage, they are more susceptible to invalidation if prior art demonstrates obviousness or anticipation.

2. How does the patent landscape influence the value of the ’451 patent?
A dense landscape with similar patents can both protect against infringers through overlapping claims and complicate enforcement. It necessitates strategic positioning, licensing negotiations, and ongoing patent prosecutions to sustain value.

3. Can competitors design around the claims of the ’451 patent?
Potentially, if they develop alternative methods or compositions outside the scope of the claims. Detailed claim parsing and landscape analysis can identify such design-arounds, emphasizing the need for precise claim drafting.

4. How does the ’451 patent fare against prior art references?
The patent appears well-supported by experimental data and argumentation to establish novelty and non-obviousness. Still, new prior art disclosures could challenge validity, requiring vigilant monitoring.

5. What strategic steps should patent holders take to maximize the impact of the ’451 patent?
They should pursue international filings to extend protection, enforce claims actively, explore licensing opportunities, and continue R&D to develop auxiliary patents, fortifying patent protection and market exclusivity.


References

  1. USPTO Patent Database for U.S. Patent 10,364,451
  2. CPC Classification Resources (E.g., Cooperative Patent Classification data)
  3. Recent patent filings and legal analyses in the relevant technical domain
  4. Prior art references cited in prosecution history and subsequent literature

More… ↓

⤷  Get Started Free

Details for Patent 10,364,451

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 January 15, 1974 10,364,451 2036-12-21
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 December 27, 1984 10,364,451 2036-12-21
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 15, 1985 10,364,451 2036-12-21
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 February 16, 1990 10,364,451 2036-12-21
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 March 26, 1974 10,364,451 2036-12-21
Fresenius Kabi Usa, Llc CHORIONIC GONADOTROPIN chorionic gonadotropin For Injection 017067 March 05, 1973 10,364,451 2036-12-21
Eli Lilly And Company HUMATROPE somatropin For Injection 019640 June 23, 1987 10,364,451 2036-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.